Stay updated on APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Sign up to get notified when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.

Latest updates to the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page
- Check4 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed study descriptions and inclusion criteria for a clinical trial involving APG-115 and pembrolizumab, while adding new identifiers and collaborators.SummaryDifference33%
- Check11 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check18 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedDifference0.6%
- Check54 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check69 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.